Phoenix and Raven Offer Eligible Canadians Ozempic® at the Same Price as Generic Semaglutide

Semaglutide just got a major price shakeup in Canada. Phoenix and Raven, two names in the research peptide world, are now offering Ozempic (the branded semaglutide compound) to eligible Canadians at the same price as generic semaglutide. This move levels the playing field for researchers who want the original branded molecule without the usual premium.

Here’s why this matters:

This shift isn’t just about saving money. It’s about flexibility and transparency in peptide sourcing. With Ozempic now at generic prices, researchers have more freedom to choose the most appropriate reference compound for their protocols. It also signals that the Canadian research supply market is heating up, with competitive offers not just on generics but on brand names too.

Looking to compare sources or find new suppliers? Check out the vendor directory to see who else is adapting to this trend.

Key takeaway: Price parity between Ozempic and generic semaglutide is a win for Canadian peptide researchers. More options, better data, and smarter budgets. Track updates on semaglutide to stay ahead in this fast-moving field.